bioRxivCancer Biology
Knowledge Graph-based Recommendation Framework Identifies Novel Drivers of Resistance in EGFR mutant Non-small Cell Lung Cancer
A. Gogleva, D. Polychronopoulos, M. Pfeifer, V. Poroshin, M. Ughetto, B. Sidders, J. Dry, M. Ahdesmaki, U. McDermott, E. Papa, K. Bulusu
Abstract
Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). One of the most exciting new ways to find potential resistance markers involves running functional genetic screens, such as CRISPR, followed by manual triage of significantly enriched genes. This triage process to identify high value hits resulting from the CRISPR screen involves significant manual curation that requires specialized knowledge and can take even experts several months to comprehensively complete. To find key drivers of resistance faster we built a hybrid recommendation system on top of a heterogeneous biomedical knowledge graph integrating preclinical, clinical, and literature evidence. Genes were ranked based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance. This unbiased approach identified 36 resistance markers from >3,000 genes, reducing hit identification time from months to minutes. In addition to reproducing known resistance markers, our method identified novel resistance mechanisms that we prospectively validated.
- organism: human
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Paired activity learning supports systematic identification of mutant-selective EGFR inhibitors
Jie Zhu, Weikaixin Kong, … Tero A. Aittokallio·bioRxiv·Oct 26, 2026
- MCB-613 exploits a collateral sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1
C. F. Bassil, G. R. Anderson, … K. C. Wood·bioRxiv·Jan 17, 2023
- Investigating EMT-mediated resistance to EGFR tyrosine kinase inhibitors in NSCLC using innovative organoid models
N. Kobayashi, S. Katakura, … T. Kaneko·bioRxiv·Feb 8, 2024
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
L. Brunet, D. Alexandre, … L. Grumolato·bioRxiv·Jun 19, 2023
- Retrospective study on the clinicogenomic characteristics of EGFR mutant and wildtype NSCLC
Chirag Dhar·CureusPeer-reviewed·Apr 25, 2021
- Intratumoral Resident Microbes Directly Participate in Resistance to EGFR-TKI Targeted Drug Therapy through Metabolism in NSCLC
Huan Wang, Jiarui Zhang, … Dan Xie·bioRxiv·Mar 12, 2025